Latest 10-K annual reports

Regen Biopharma, Inc. filed its annual 10-K, revealing a significant increase in net loss to $1.27 million and substantial doubt about its ability to continue as a going concern, despite reduced operating cash burn.

Global Technologies, Ltd. reported a net loss of $342,681 for fiscal year 2025, driven by a strategic pivot to health technology and a restatement of prior year financials.

Daily Journal Corporation announced a significant increase in net income and EPS for fiscal year 2025, driven by strong performance in its Journal Technologies segment and substantial unrealized gains from its marketable securities portfolio.

Cemtrex, Inc. reported a substantial net loss of $28.3 million for fiscal year 2025, alongside significant capital raises and ongoing Nasdaq listing challenges, despite revenue growth in its Security and Industrial Services segments.

Fuse Group Holding Inc. reported a significant revenue drop and increased net losses for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern.

Good Times Restaurants Inc. reported a slight revenue decrease and negative same-store sales for fiscal 2025, alongside a significant drop in net income, despite an increase in Bad Daddys' operating income.

IB Acquisition Corp. secured a business combination deadline extension to March 2026, but faced substantial share redemptions, significantly reducing its trust account balance.

Bodhi Tree Biotechnology Inc., an early-stage plant-based consulting firm, reported a significant increase in net loss and a decrease in revenue for the fiscal year ended September 30, 2025, alongside challenges in internal controls and market liquidity.

Standex International Corporation filed an amendment to its annual report to formally include its SEC-mandated Compensation Clawback Policy, adopted in August 2023.

CEL-SCI Corporation's latest 10-K filing highlights positive Phase III Multikine data for head and neck cancer, outlining plans for a confirmatory study while facing ongoing financial losses and a going concern doubt.

Graphjet Technology has been delisted from Nasdaq to OTC Pink Limited due to multiple non-compliance issues, while auditors express substantial doubt about its ability to continue as a going concern.

Broadway Financial Corporation has restated its 2024 and 2023 financial statements due to accounting errors related to loan participation agreements, reporting a significant drop in net income and diluted EPS for 2024.

VoIP-Pal.Com Inc. filed its annual 10-K, revealing a net loss of $6.2 million, an accumulated deficit exceeding $109 million, and significant going concern uncertainties, despite reduced operating expenses.

Texas Mineral Resources Corp. files an amended annual report to update corporate governance, executive compensation, and related party transaction disclosures for the fiscal year ended August 31, 2025.

Citius Pharmaceuticals, Inc. reports a net loss of $39.7 million for fiscal year 2025, with its subsidiary Citius Oncology launching LYMPHIR amidst ongoing funding needs and product development.

Citius Oncology launched its lead product LYMPHIR in December 2025, but faces substantial doubt about its ability to continue as a going concern due to recurring losses and a need for significant additional funding.

Barnwell Industries reported a significant net loss for fiscal year 2025, driven by decreased oil and natural gas revenues, asset sales, and substantial legal expenses, despite a recent capital raise.

Limoneira Company reported a significant net loss for fiscal year 2025, driven by decreased agribusiness revenue and strategic operational changes, while advancing real estate projects and debt restructuring.

Collab Z Inc. reported a net loss of $102,195 for fiscal year 2025, a significant decline from the prior year's net income, as it pivots to its AI-enhanced community-based property management platform and phases out other real estate services.

Innovative Solutions and Support, Inc., now Innovative Aerosystems, reported significant revenue and net income growth for fiscal year 2025, driven by strategic acquisitions and commercial expansion.

Barnes & Noble Education, Inc. files its restated annual report, revealing financial adjustments, growth in affordable course material programs, and significant governance and financing changes.

HEICO Corporation achieved record net sales of $4.485 billion and net income of $690.4 million in fiscal 2025, reflecting strong organic growth and strategic acquisitions across its Flight Support and Electronic Technologies segments.

Hovnanian Enterprises reports a significant decrease in net income and gross margin for fiscal 2025 despite increased home deliveries, driven by higher incentives and debt extinguishment losses.

enGene Holdings Inc. reported increased net losses for fiscal year 2025 while advancing its lead bladder cancer therapy, detalimogene, towards a planned BLA submission in late 2026.

SIFCO Industries, Inc. significantly narrowed its net loss in fiscal year 2025, driven by increased sales in aerospace and energy, improved margins, and a strategic divestiture of its European operations.

Synopsys achieved 15% revenue growth in fiscal 2025, driven by the Ansys acquisition and Design Automation strength, despite Design IP weakness and increased debt.

BNB Plus Corp. (formerly Applied DNA Sciences, Inc.) has completed a strategic pivot to a digital asset treasury model focused on BNB, while reporting a significantly wider net loss for fiscal year 2025.

Agilent Technologies achieved 7% net revenue growth in fiscal year 2025, reaching $6.95 billion, driven by strong performance in Life Sciences and Diagnostics Markets, alongside strategic restructuring and share repurchases.

Mercer Bancorp, Inc. reported a 40.4% increase in net income for fiscal year 2025, reaching $972,000, despite a notable rise in non-performing loans.

Outlook Therapeutics received a second Complete Response Letter from the FDA for its wet AMD treatment, ONS-5010/LYTENAVA, citing insufficient evidence of effectiveness, despite recent EU and UK market authorizations.